Trial Profile
A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 18 May 2010 Actual end date (1 Apr 2010) added as reported by ClinicalTrials.gov.
- 18 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.